Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial

Lancet. 1982 Nov 13;2(8307):1059-61. doi: 10.1016/s0140-6736(82)90002-2.


The effects of a new microencapsulated potassium chloride formulation on upper gastrointestinal tract mucosa was compared with that of a popular wax-matrix formulation in 48 healthy volunteers. After a week of KCl, subjects were gastroscoped, the endoscopist being blind to the type of preparation taken. Wax-matrix formulations were associated with a higher incidence of upper gastrointestinal lesions. The lesions were not accompanied by epigastric symptoms. Glycopyrrolate, given to some volunteers to decrease gastric emptying, aggravated the effects of potassium chloride.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Acute Disease
  • Adult
  • Clinical Trials as Topic
  • Delayed-Action Preparations
  • Drug Synergism
  • Gastric Mucosa / drug effects*
  • Gastrointestinal Diseases / chemically induced*
  • Gastrointestinal Hemorrhage / chemically induced
  • Glycopyrrolate / adverse effects
  • Humans
  • Intestinal Mucosa / drug effects*
  • Male
  • Peptic Ulcer / chemically induced
  • Peptic Ulcer Perforation / chemically induced
  • Potassium Chloride / administration & dosage
  • Potassium Chloride / adverse effects*


  • Delayed-Action Preparations
  • Potassium Chloride
  • Glycopyrrolate